ZA201906832B - Novel psma-binding agents and uses thereof - Google Patents
Novel psma-binding agents and uses thereofInfo
- Publication number
- ZA201906832B ZA201906832B ZA2019/06832A ZA201906832A ZA201906832B ZA 201906832 B ZA201906832 B ZA 201906832B ZA 2019/06832 A ZA2019/06832 A ZA 2019/06832A ZA 201906832 A ZA201906832 A ZA 201906832A ZA 201906832 B ZA201906832 B ZA 201906832B
- Authority
- ZA
- South Africa
- Prior art keywords
- binding agents
- novel psma
- psma
- novel
- radiopharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- High Energy & Nuclear Physics (AREA)
- Radiology & Medical Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000891 | 2017-05-24 | ||
| PCT/EP2017/000717 WO2018233798A1 (en) | 2017-06-20 | 2017-06-20 | Novel psma-binding agents and uses thereof |
| PCT/EP2018/063734 WO2018215627A1 (en) | 2017-05-24 | 2018-05-24 | Novel psma-binding agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201906832B true ZA201906832B (en) | 2024-02-28 |
Family
ID=62200468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/06832A ZA201906832B (en) | 2017-05-24 | 2019-10-16 | Novel psma-binding agents and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11629201B2 (enExample) |
| EP (1) | EP3630204A1 (enExample) |
| JP (1) | JP7340459B2 (enExample) |
| KR (1) | KR102843240B1 (enExample) |
| CN (1) | CN110740757B (enExample) |
| AU (1) | AU2018274184B2 (enExample) |
| CA (1) | CA3060143A1 (enExample) |
| WO (1) | WO2018215627A1 (enExample) |
| ZA (1) | ZA201906832B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200339625A1 (en) * | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| US12228480B2 (en) * | 2018-11-30 | 2025-02-18 | Revvity Health Sciences, Inc. | Biological sample preparation using electric fields |
| AU2020208492A1 (en) * | 2019-01-17 | 2021-08-12 | Case Western Reserve University | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix |
| US12472272B2 (en) | 2019-04-17 | 2025-11-18 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer |
| EP3976025A4 (en) * | 2019-05-24 | 2023-05-17 | Clarity Pharmaceuticals Limited | PSMA IMAGING AGENT FORMULATIONS |
| AU2020296488A1 (en) | 2019-06-21 | 2022-01-20 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| TWI803688B (zh) * | 2019-08-26 | 2023-06-01 | 行政院原子能委員會核能研究所 | 一種psma靶向放射診療藥物備製方法 |
| KR102269315B1 (ko) * | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| WO2022096103A1 (en) | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| CA3210294A1 (en) * | 2021-03-04 | 2022-09-09 | Yoshifumi Maya | Compound and radioactive labeling compound |
| CA3223227A1 (en) * | 2021-05-21 | 2022-11-24 | NorthStar Medical Technologies, LLC | Urokinase plasminogen activator receptor-targeted radiopharmaceutical |
| WO2023030509A1 (zh) * | 2021-09-03 | 2023-03-09 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| TW202321204A (zh) * | 2021-11-10 | 2023-06-01 | 大陸商蘇州瑞核醫藥科技有限公司 | 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用 |
| EP4436979A1 (en) * | 2021-11-26 | 2024-10-02 | Full-Life Technologies HK Limited | Cleavable radioligands for targeting cell surface receptors and uses thereof |
| AU2023226956A1 (en) * | 2022-03-04 | 2024-09-12 | Provincial Health Services Authority | Radiolabeled compounds targetng the prostate-specific membrane antigen |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| KR20250057886A (ko) * | 2022-09-07 | 2025-04-29 | 쓰리비 파마슈티컬스 게엠베하 | 전립선 특이적 막 항원 (psma) 리간드 및 그의 용도 |
| WO2024051794A1 (zh) * | 2022-09-09 | 2024-03-14 | 同宜医药（苏州）有限公司 | 放射性核素偶联药物及其药物组合物和应用 |
| CN120282804A (zh) * | 2022-09-23 | 2025-07-08 | 核素迪姆股份公司 | 高纯度铜放射性药物组合物及其诊断和治疗用途 |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| KR20250148672A (ko) * | 2023-02-16 | 2025-10-14 | 노로이 바이오사이언스 씨오., 엘티디. | Psma 표적 방사성 약물 및 그 합성과 응용 |
| WO2024245421A1 (en) * | 2023-05-31 | 2024-12-05 | Full-Life Technologies Hk Limited | Radioligands for targeting cell surface receptors and uses thereof |
| AU2024282453A1 (en) * | 2023-05-31 | 2025-12-04 | Full-Life Technologies Hk Limited | Conjugates and uses thereof |
| CN120265331A (zh) | 2023-07-31 | 2025-07-04 | 美国锔责任有限公司 | [177Lu]镥-PSMA I&T组合物及其剂量测定、试剂盒、制备方法和使用方法 |
| WO2025088147A1 (en) * | 2023-10-27 | 2025-05-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis |
| WO2025218879A1 (en) | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US9687572B2 (en) * | 2010-12-06 | 2017-06-27 | Molecular Insight Pharmaceuticals, Inc. | PSMA-targeted dendrimers |
| ES2732060T3 (es) | 2011-08-05 | 2019-11-20 | Molecular Insight Pharm Inc | Inhibidores radiomarcados del antígeno de membrana específico de la próstata |
| HUE068833T2 (hu) | 2011-08-17 | 2025-01-28 | Merck & Cie Kmg | Albumint megkötõ egységek folát konjugátjai |
| ES2743433T3 (es) | 2013-03-15 | 2020-02-19 | Cancer Targeted Tech Llc | Agentes para imágenes de pet dirigidos a psma marcados con 18F |
| AU2014336638C1 (en) * | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2018031809A1 (en) | 2016-08-10 | 2018-02-15 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
-
2018
- 2018-05-24 KR KR1020197038065A patent/KR102843240B1/ko active Active
- 2018-05-24 CN CN201880034324.3A patent/CN110740757B/zh active Active
- 2018-05-24 JP JP2019562312A patent/JP7340459B2/ja active Active
- 2018-05-24 AU AU2018274184A patent/AU2018274184B2/en active Active
- 2018-05-24 EP EP18725856.1A patent/EP3630204A1/en active Pending
- 2018-05-24 WO PCT/EP2018/063734 patent/WO2018215627A1/en not_active Ceased
- 2018-05-24 US US16/616,744 patent/US11629201B2/en active Active
- 2018-05-24 CA CA3060143A patent/CA3060143A1/en active Pending
-
2019
- 2019-10-16 ZA ZA2019/06832A patent/ZA201906832B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200009091A (ko) | 2020-01-29 |
| CA3060143A1 (en) | 2018-11-29 |
| RU2019141963A (ru) | 2021-06-24 |
| JP7340459B2 (ja) | 2023-09-07 |
| AU2018274184A1 (en) | 2019-11-07 |
| CN110740757B (zh) | 2023-04-04 |
| JP2020520902A (ja) | 2020-07-16 |
| RU2019141963A3 (enExample) | 2021-09-22 |
| CN110740757A (zh) | 2020-01-31 |
| AU2018274184B2 (en) | 2024-06-13 |
| US20210009715A1 (en) | 2021-01-14 |
| KR102843240B1 (ko) | 2025-08-05 |
| US11629201B2 (en) | 2023-04-18 |
| WO2018215627A1 (en) | 2018-11-29 |
| EP3630204A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| JOP20200022A1 (ar) | مركبات حلقية لولبية وطرق تصنيعها واستخدامها | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| WO2015120062A3 (en) | Therapeutic compounds and compositions | |
| MX2020002251A (es) | Compuestos espirociclicos y sus metodos de preparacion y uso. | |
| NZ778138A (en) | Therapeutic binding compounds | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| EA202090107A2 (ru) | Композиции, содержащие бактериальные штаммы | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro |